Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates & calculations
1.4 Forecast calculations
1.5 Data sources
1.6 Primary
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Aquaculture Vaccines industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Type of vaccines trends
2.1.3 Route of administration trends
2.1.4 Application trends
2.1.5 Species trends
2.1.6 Regional trends
Chapter 3 Aquaculture Vaccines Industry Insights
3.1 Industry ecosystem analysis
3.2 Vendor matrix
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Surging prevalence of bacterial and viral infections
3.3.1.2 Increasing aquaculture production across the globe
3.3.1.3 Development and launch of new aquaculture vaccines
3.3.1.4 Rising adoption of aquaculture vaccines over antibiotics
3.3.2 Industry pitfalls & challenges
3.3.2.1 Stringent regulatory policies for vaccine approval
3.3.2.2 Complex vaccine development procedures
3.4 Growth potential analysis
3.4.1 By type of vaccines
3.4.2 By route of administration
3.4.3 By application
3.4.4 By species
3.5 Regulatory scenario
3.5.1 U.S.
3.5.2 Canada
3.5.3 Europe
3.6 Porter’s analysis
3.6.1 Industry rivalry
3.6.2 Buyer power
3.6.3 Supplier power
3.6.4 Threat of substitute
3.6.5 Threat of new entrants
3.7 PESTEL analysis
3.7.1 Political
3.7.2 Economical
3.7.3 Social
3.7.4 Technological
3.7.5 Environmental
3.7.6 Legal
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Product portfolio matrix
4.2.1 Zoetis Inc.
4.2.2 Merck & Co., Inc.
4.2.3 HIPRA
4.2.4 Tecnovax
4.2.5 Virbac
4.2.6 Veterquimica S.A.
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic outlook matrix
Chapter 5 Aquaculture Vaccines Market, By Type of vaccines
5.1 Key segment trends
5.2 Inactivated vaccines
5.2.1 Market size, by region, 2018 – 2032 (USD Million)
5.3 Live vaccines
5.3.1 Market size, by region, 2018 – 2032 (USD Million)
Chapter 6 Aquaculture Vaccines Market, By Route of Administration
6.1 Key segment trends
6.2 Immersion vaccines
6.2.1 Market size, by region, 2018 - 2032 (USD Million)
6.3 Injection vaccines
6.3.1 Market size, by region, 2018 - 2032 (USD Million)
6.4 Oral vaccines
6.4.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 7 Aquaculture Vaccines Market, By Application
7.1 Key segment trends
7.2 Bacterial infection
7.2.1 Market size, by region, 2018 - 2032 (USD Million)
7.3 Viral Infection
7.3.1 Market size, by region, 2018 - 2032 (USD Million)
7.4 Others
7.4.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 8 Aquaculture Vaccines Market, By Species
8.1 Key segment trends
8.2 Salmon
8.2.1 Market size, by region, 2018 - 2032 (USD Million)
8.3 Trout
8.3.1 Market size, by region, 2018 - 2032 (USD Million)
8.4 Tilapia
8.4.1 Market size, by region, 2018 - 2032 (USD Million)
8.5 Others
8.5.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 9 Aquaculture Vaccines Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 Market size, by country, 2018 - 2032
9.2.2 Market size, by type of vaccines, 2018 - 2032
9.2.3 Market size, by route of administration, 2018 - 2032
9.2.4 Market size, by application, 2018 - 2032
9.2.5 Market size, by species, 2018 - 2032
9.2.2 U.S.
9.2.2.1 Market size, by type of vaccines, 2018 - 2032
9.2.2.2 Market size, by route of administration, 2018 - 2032
9.2.2.3 Market size, by application, 2018 - 2032
9.2.2.4 Market size, by species, 2018 - 2032
9.2.3 Canada
9.2.3.1 Market size, by type of vaccines, 2018 - 2032
9.2.3.2 Market size, by route of administration, 2018 - 2032
9.2.3.3 Market size, by application, 2018 - 2032
9.2.3.4 Market size, by species, 2018 - 2032
9.3 Europe
9.3.1 Market size, by country, 2018 - 2032
9.3.2 Market size, by type of vaccines, 2018 - 2032
9.3.3 Market size, by route of administration, 2018 - 2032
9.3.4 Market size, by application, 2018 - 2032
9.3.5 Market size, by species, 2018 - 2032
9.3.2 Germany
9.3.2.1 Market size, by type of vaccines, 2018 - 2032
9.3.2.2 Market size, by route of administration, 2018 - 2032
9.3.2.3 Market size, by application, 2018 - 2032
9.3.2.4 Market size, by species, 2018 - 2032
9.3.3 UK
9.3.3.1 Market size, by type of vaccines, 2018 - 2032
9.3.3.2 Market size, by route of administration, 2018 - 2032
9.3.3.3 Market size, by application, 2018 - 2032
9.3.3.4 Market size, by species, 2018 - 2032
9.3.4 France
9.3.4.1 Market size, by type of vaccines, 2018 - 2032
9.3.4.2 Market size, by route of administration, 2018 - 2032
9.3.4.3 Market size, by application, 2018 - 2032
9.3.4.4 Market size, by species, 2018 - 2032
9.3.5 Spain
9.3.5.1 Market size, by type of vaccines, 2018 - 2032
9.3.5.2 Market size, by route of administration, 2018 - 2032
9.3.5.3 Market size, by application, 2018 - 2032
9.3.5.4 Market size, by species, 2018 - 2032
9.3.6 Italy
9.3.6.1 Market size, by type of vaccines, 2018 - 2032
9.3.6.2 Market size, by route of administration, 2018 - 2032
9.3.6.3 Market size, by application, 2018 - 2032
9.3.6.4 Market size, by species, 2018 - 2032
9.3.7 Norway
9.3.7.1 Market size, by type of vaccines, 2018 - 2032
9.3.7.2 Market size, by route of administration, 2018 - 2032
9.3.7.3 Market size, by application, 2018 - 2032
9.3.7.4 Market size, by species, 2018 - 2032
9.3.8 Ireland
9.3.8.1 Market size, by type of vaccines, 2018 - 2032
9.3.8.2 Market size, by route of administration, 2018 - 2032
9.3.8.3 Market size, by application, 2018 - 2032
9.3.8.4 Market size, by species, 2018 - 2032
9.3.9 Turkey
9.3.9.1 Market size, by type of vaccines, 2018 - 2032
9.3.9.2 Market size, by route of administration, 2018 - 2032
9.3.9.3 Market size, by application, 2018 - 2032
9.3.9.4 Market size, by species, 2018 - 2032
9.3.10 Denmark
9.3.10.1 Market size, by type of vaccines, 2018 - 2032
9.3.10.2 Market size, by route of administration, 2018 - 2032
9.3.10.3 Market size, by application, 2018 - 2032
9.3.10.4 Market size, by species, 2018 - 2032
9.4 Asia Pacific
9.4.1 Market size, by country, 2018 - 2032
9.4.2 Market size, by type of vaccines, 2018 - 2032
9.4.3 Market size, by route of administration, 2018 - 2032
9.4.4 Market size, by application, 2018 - 2032
9.4.5 Market size, by species, 2018 - 2032
9.4.2 China
9.4.2.1 Market size, by type of vaccines, 2018 - 2032
9.4.2.2 Market size, by route of administration, 2018 - 2032
9.4.2.3 Market size, by application, 2018 - 2032
9.4.2.4 Market size, by species, 2018 - 2032
9.4.3 Indonesia
9.4.3.1 Market size, by type of vaccines, 2018 - 2032
9.4.3.2 Market size, by route of administration, 2018 - 2032
9.4.3.3 Market size, by application, 2018 - 2032
9.4.3.4 Market size, by species, 2018 - 2032
9.4.4 Philippines
9.4.4.1 Market size, by type of vaccines, 2018 - 2032
9.4.4.2 Market size, by route of administration, 2018 - 2032
9.4.4.3 Market size, by application, 2018 - 2032
9.4.4.4 Market size, by species, 2018 - 2032
9.4.5 Thailand
9.4.5.1 Market size, by type of vaccines, 2018 - 2032
9.4.5.2 Market size, by route of administration, 2018 - 2032
9.4.5.3 Market size, by application, 2018 - 2032
9.4.5.4 Market size, by species, 2018 - 2032
9.4.6 Australia
9.4.6.1 Market size, by type of vaccines, 2018 - 2032
9.4.6.2 Market size, by route of administration, 2018 - 2032
9.4.6.3 Market size, by application, 2018 - 2032
9.4.6.4 Market size, by species, 2018 - 2032
9.4.7 New Zealand
9.4.7.1 Market size, by type of vaccines, 2018 - 2032
9.4.7.2 Market size, by route of administration, 2018 - 2032
9.4.7.3 Market size, by application, 2018 - 2032
9.4.7.4 Market size, by species, 2018 - 2032
9.5 Latin America
9.5.1 Market size, by country, 2018 - 2032
9.5.2 Market size, by type of vaccines, 2018 - 2032
9.5.3 Market size, by route of administration, 2018 - 2032
9.5.4 Market size, by application, 2018 - 2032
9.5.5 Market size, by species, 2018 - 2032
9.5.2 Brazil
9.5.2.1 Market size, by type of vaccines, 2018 - 2032
9.5.2.2 Market size, by route of administration, 2018 - 2032
9.5.2.3 Market size, by application, 2018 - 2032
9.5.2.4 Market size, by species, 2018 - 2032
9.5.3 Mexico
9.5.3.1 Market size, by type of vaccines, 2018 - 2032
9.5.3.2 Market size, by route of administration, 2018 - 2032
9.5.3.3 Market size, by application, 2018 - 2032
9.5.3.4 Market size, by species, 2018 - 2032
9.5.4 Chile
9.5.4.1 Market size, by type of vaccines, 2018 - 2032
9.5.4.2 Market size, by route of administration, 2018 - 2032
9.5.4.3 Market size, by application, 2018 - 2032
9.5.4.4 Market size, by species, 2018 - 2032
9.6 MEA
9.6.1 Market size, by country, 2018 - 2032
9.6.2 Market size, by type of vaccines, 2018 - 2032
9.6.3 Market size, by route of administration, 2018 - 2032
9.6.4 Market size, by application, 2018 - 2032
9.6.5 Market size, by species, 2018 - 2032
9.6.2 Iran
9.6.2.1 Market size, by type of vaccines, 2018 - 2032
9.6.2.2 Market size, by route of administration, 2018 - 2032
9.6.2.3 Market size, by application, 2018 - 2032
9.6.2.4 Market size, by species, 2018 - 2032
9.6.3 Egypt
9.6.3.1 Market size, by type of vaccines, 2018 - 2032
9.6.3.2 Market size, by route of administration, 2018 - 2032
9.6.3.3 Market size, by application, 2018 - 2032
9.6.3.4 Market size, by species, 2018 - 2032
Chapter 10 Company Profiles
10.1 Hipra
10.1.1 Business overview
10.1.2 Financial data
10.1.3 Product landscape
10.1.4 Strategic outlook
10.1.5 SWOT analysis
10.2 Zoetis Inc.
10.2.1 Business overview
10.2.2 Financial data
10.2.3 Product landscape
10.2.4 Strategic outlook
10.2.5 SWOT analysis
10.3 Merck & Co., Inc.
10.3.1 Business overview
10.3.2 Financial data
10.3.3 Product landscape
10.3.4 Strategic outlook
10.3.5 SWOT analysis
10.4 Tecnovax
10.4.1 Business overview
10.4.2 Financial data
10.4.3 Product landscape
10.4.4 Strategic outlook
10.4.5 SWOT analysis
10.5 Virbac
10.5.1 Business overview
10.5.2 Financial data
10.5.3 Product landscape
10.5.4 Strategic outlook
10.5.5 SWOT analysis
10.6 Veterquimica S.A.
10.6.1 Business overview
10.6.2 Financial data
10.6.3 Product landscape
10.6.4 Strategic outlook
10.6.5 SWOT analysis
10.7 Nisseiken Co. Ltd.
10.7.1 Business overview
10.7.2 Financial data
10.7.3 Product landscape
10.7.4 Strategic outlook
10.7.5 SWOT analysis
10.8 Phibro Animal Health Corporation
10.8.1 Business overview
10.8.2 Financial data
10.8.3 Product landscape
10.8.4 Strategic outlook
10.8.5 SWOT analysis
10.9 Vaxxinova International BV
10.9.1 Business overview
10.9.2 Financial data
10.9.3 Product landscape
10.9.4 Strategic outlook
10.9.5 SWOT analysis
10.10 Kyoto Biken Laboratories, Inc
10.10.1 Business overview
10.10.2 Financial data
10.10.3 Product landscape
10.10.4 Strategic outlook
10.10.5 SWOT analysis
